Publications by authors named "Jan Buter"

Claim this Profile
R
Recurrent Hematological Toxicity After Second-Line Treatment in Patients with Glioblastoma: Indication of a Potential Predisposition.
Leon van Hout, Femke E L van den Elzen, Zoë de Jong, Nienke Grun, Martinus P G Broen, Jan Buter

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records.
Alessandro De Carlo, Elena Maria Tosca, Mirjam Crul, Tim Schutte, Lia van Zuijlen, Jan Buter

Br J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
Ilse A C Spiekman, Birgit S Geurts, Laurien J Zeverijn, Gijs F de Wit, Vincent van der Noort, Jan Buter

Oncologist· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
Reinout H de Roest, Martijn van der Heijden, Frederik W R Wesseling, Emma J de Ruiter, Martijn W Heymans, Jan Buter

Radiother Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis.
Youri Hoogstrate, Santoesha A Ghisai, Maurice de Wit, Iris de Heer, Kaspar Draaisma, Jan Buter

Neuro Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.
Renske Gahrmann, Marion Smits, René Michel Vernhout, Walter Taal, Giorgios Kapsas, Jan Buter

Neurooncol Adv· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Saskia H Hanemaaijer, Iris C Kok, Rudolf S N Fehrmann, Bert van der Vegt, Jourik A Gietema, Jan Buter

Front Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Hisham Mehanna, Max Robinson, Andrew Hartley, Anthony Kong, Bernadette Foran, Jan Buter

Lancet· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Eline Boon, Wim van Boxtel, Jan Buter, Robert J Baatenburg de Jong, Robert J J van Es

Head Neck· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Renske Gahrmann, Martin van den Bent, Bronno van der Holt, René Michel Vernhout, Walter Taal, Jan Buter

Neuro Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in patterns of survival in metastatic adenoid cystic carcinoma of the head and neck.
Stijn van Weert, Rinze Reinhard, Elisabeth Bloemena, Jan Buter, Birgit I Witte

Head Neck· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12-week guided home-based program.
Ingrid C Cnossen, Cornelia F van Uden-Kraan, Birgit I Witte, Yke J Aalders, Cees J T de Goede, Jan Buter

Eur Arch Otorhinolaryngol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.
Eline Boon, Winette T A van der Graaf, Hans Gelderblom, Margot E T Tesselaar, Robert J J van Es, Jan Buter

Head Neck· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma.
Myra E van Linde, Johannes C van der Mijn, Thang V Pham, Jaco C Knol, Laurine E Wedekind, Jan Buter

J Neurooncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI.
Rico N Rinkel, Irma M Verdonck-de Leeuw, Patricia Doornaert, Jan Buter, Remco de Bree

Eur Arch Otorhinolaryngol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer.
Jolien Heukelom, Marta Lopez-Yurda, Alfons J M Balm, Oda B Wijers, Jan Buter

Head Neck· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands.
Naomi van der Linden, Jan Buter, Chris P Pescott, Roy I Lalisang, Jan Paul de Boer

Eur Arch Otorhinolaryngol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Lale Erdem-Eraslan, Martin J van den Bent, Youri Hoogstrate, Hina Naz-Khan, Andrew Stubbs, Jan Buter

Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, Hendrikus J Dubbink, Laurens V Beerepoot, Jan Buter

Lancet Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study.
Irma M Verdonck-de Leeuw, Laurien M Buffart, Martijn W Heymans, Derek H Rietveld, Patricia Doornaert, Jan Buter

Radiother Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation.
Jelle J Lindenberg, Dinja Oosterhoff, Claudia C Sombroek, Sinéad M Lougheed, Erik Hooijberg, Jan Buter

PLoS One· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent dyspnea following a swollen leg in a 46-year-old man.
Judith P Post, Hans M Westgeest, Jan D Blankensteijn, Bram van der Meijs, Rob J L Klaassen, Jan Buter

Chest· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice.
Ingrid C Cnossen, Remco de Bree, Rico N P M Rinkel, Simone E J Eerenstein, Derek H F Rietveld, Jan Buter

Support Care Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Maaike J Vos, Johannes Berkhof, Otto S Hoekstra, Ingeborg Bosma, Eefje M Sizoo, Jan Buter

Neuroradiology· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer.
Joost L Knegjens, Michael Hauptmann, Frank A Pameijer, Alfons J Balm, Frank J Hoebers, Jan Buter

Head Neck· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis